No, at the Pancreatic Cancer Symposium's I've attended Doctor's who were working the PACT Trial were enthusiastic about the numbers of resections in TNFerade patients, I believe that should show when we get all the data. Unfortunately, that's a secondary endpoint that cannot of itself gain approval, even if some patients ultimately are deemed to be cured. I'm sure this is the case with our landscaper.
Years ago I learned of patients thought to be cured by drugs which were abandoned, it happens more frequently than anyone probably wants to admit.
I'm not sure if a trial couldn't be sold to the FDA where resections were the goal in Pancreatic Cancer. We know most who are resected still die, but the few cures that do occur happen in patients who's cancer is resected.
While there is no telling if the trial using TNFerade with another experimental drug could lead to approvals of both until we see data, to me that still makes it possible.
Gary
